<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40012840</article-id><article-id pub-id-type="pmc">PMC11860084</article-id><article-id pub-id-type="publisher-id">1451164</article-id><article-id pub-id-type="doi">10.3389/fphar.2024.1451164</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Novel (Q)SAR models for prediction of reversible and time-dependent inhibition of cytochrome P450 enzymes</article-title><alt-title alt-title-type="left-running-head">Faramarzi et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2024.1451164" ext-link-type="uri">10.3389/fphar.2024.1451164</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Faramarzi</surname><given-names>Sadegh</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2770843/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bassan</surname><given-names>Arianna</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2626751/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Cross</surname><given-names>Kevin P.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xinning</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2162390/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Myatt</surname><given-names>Glenn J.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Volpe</surname><given-names>Donna A.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2159488/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Stavitskaya</surname><given-names>Lidiya</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1940698/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Office of Clinical Pharmacology</institution>, <institution>Center for Drug Evaluation and Research</institution>, <institution>Food and Drug Administration</institution>, <addr-line>Silver Spring</addr-line>, <addr-line>MD</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Instem Inc.</institution>, <addr-line>Conshohocken</addr-line>, <addr-line>PA</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/1872270/overview" ext-link-type="uri">Charles Oo</ext-link>, Morris Plains, United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/2729013/overview" ext-link-type="uri">Gajanan Jadhav</ext-link>, University of Alabama at Birmingham, United States</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/61306/overview" ext-link-type="uri">Sam P. De Visser</ext-link>, The University of Manchester, United Kingdom</p></fn><corresp id="c001">*Correspondence: Lidiya Stavitskaya, <email>lidiya.stavitskaya@fda.hhs.gov</email>
</corresp><fn fn-type="equal" id="fn001"><label>
<sup>&#x02020;</sup>
</label><p>These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><elocation-id>1451164</elocation-id><history><date date-type="received"><day>18</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Faramarzi, Bassan, Cross, Yang, Myatt, Volpe and Stavitskaya.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Faramarzi, Bassan, Cross, Yang, Myatt, Volpe and Stavitskaya</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The 2020 FDA drug-drug interaction (DDI) guidance includes a consideration for metabolites with structural alerts for potential mechanism-based inhibition (MBI) and describes how this information may be used to determine whether <italic>in vitro</italic> studies need to be conducted to evaluate the inhibitory potential of a metabolite on CYP enzymes. To facilitate identification of structural alerts, an extensive literature search was performed and alerts for mechanism-based inhibition of cytochrome P450 enzymes (CYP) were collected. Furthermore, five quantitative structure-activity relationship (QSAR) models were developed to predict not only time-dependent inhibition of CYP3A4, an enzyme that metabolizes approximately 50% of all marketed drugs, but also reversible inhibition of 3A4, 2C9, 2C19 and 2D6. The non-proprietary training database for the QSAR models contains data for 10,129 chemicals harvested from FDA drug approval packages and published literature. The cross-validation performance statistics for the new CYP QSAR models range from 78% to 84% sensitivity and 79%&#x02013;84% normalized negative predictivity. Additionally, the performance of the newly developed QSAR models was assessed using external validation sets. Overall performance statistics showed up to 75% in sensitivity and up to 80% in normalized negative predictivity. The newly developed models will provide a faster and more effective evaluation of potential drug-drug interaction caused by metabolites.</p></abstract><kwd-group><kwd>CYP = cytochrome P450</kwd><kwd>reversible inhibition</kwd><kwd>time dependent inhibition</kwd><kwd>QSAR</kwd><kwd>SAR</kwd><kwd>computational model</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. SF was supported by an appointment to the Research Participation Program at CDER, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy and the FDA.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Drug Metabolism and Transport</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Cytochrome P450 (CYP) enzymes are a family of heme containing enzymes that catalyze the oxidative metabolism of drugs, chemical carcinogens, steroids, and fatty acids (<xref rid="B24" ref-type="bibr">Guengerich, 2001</xref>). Drugs and other xenobiotics may inhibit or induce CYP enzymes, and therefore alter the metabolism of co-administered drugs. This phenomenon makes up the majority of drug-drug interaction (DDI) (<xref rid="B28" ref-type="bibr">Hansten et al., 2010</xref>). DDI has led to withdrawal of drugs such as mibefradil, terfenadine, bromfenac, cisapride, cerivastatin, <italic>etc.</italic>, from the market (<xref rid="B61" ref-type="bibr">Wienkers and Heath, 2005</xref>; <xref rid="B22" ref-type="bibr">Giacomini et al., 2007</xref>; <xref rid="B45" ref-type="bibr">O Nettleton and J Einolf, 2011</xref>). Adverse drug reactions from DDIs are also the fourth leading cause of death in the US (<xref rid="B5" ref-type="bibr">Borda et al., 1968</xref>; <xref rid="B11" ref-type="bibr">Costa, 1991</xref>).</p><p>There are at least 57 human CYP enzymes among which 12 have been reported to be involved in drug metabolism (<xref rid="B42" ref-type="bibr">Lewis and Ito, 2010</xref>). It was reported that 52% of small molecule drugs approved by the U.S. FDA in 2015&#x02013;2020 were metabolized by CYP3A4, making it the major CYP subtype (<xref rid="B25" ref-type="bibr">Guengerich, 2022</xref>). CYP enzyme inhibition is generally categorized as reversible or irreversible. Mechanism-based inhibition (MBI) is a sub-category of irreversible inhibition, while reversible inhibition (RI) usually occurs when two or more molecules compete for binding to active or allosteric sites of a CYP enzyme. RI can also be non-competitive, where the inhibitor the inhibitor alters the active site of the enzyme so that the enzyme loses affinity for its substrate (<xref rid="B13" ref-type="bibr">Deodhar et al., 2020</xref>). MBI typically involves the conversion of a drug to a reactive metabolite(s), which may react with components of cellular proteins, DNA, and may even lead to enzyme destruction (<xref rid="B66" ref-type="bibr">Zhang and Tang, 2018</xref>). The MBI mechanism leads to a change in potency of CYP inhibitors that depends on <italic>in vitro</italic> incubation time or dosing period <italic>in vivo</italic>, and this change is referred to as time-dependent inhibition (TDI) (<xref rid="B48" ref-type="bibr">Riley et al., 2007</xref>). As a result, CYP inhibition presents a great risk in drug development process.</p><p>In 2020, FDA finalized a guidance to assist drug developers with evaluating the DDI potential of investigational drugs (<ext-link xlink:href="http://www.fda.gov/media/134582/download" ext-link-type="uri">www.fda.gov/media/134582/download</ext-link>). Specifically, the guidance provides a framework for conducting and interpreting <italic>in vitro</italic> studies for new drugs. Furthermore, the guidance states that <italic>in vivo</italic> DDI caused by metabolites may be possible even if the <italic>in vitro</italic> studies suggest that the parent drug alone will not inhibit any major CYP enzymes (<ext-link xlink:href="http://www.fda.gov" ext-link-type="uri">www.fda.gov</ext-link>) (<xref rid="B54" ref-type="bibr">Sudsakorn et al., 2020</xref>). Therefore, the guidance recommends that drug developers consider evaluating metabolites <italic>in vitro</italic> for their inhibitory effects on a panel of CYP enzymes. Specifically, an <italic>in vitro</italic> CYP enzyme inhibition study is recommended &#x0201c;if the metabolite is (1) less polar than the parent drug and the area under the plasma concentration-time curve (AUC) of a metabolite is &#x02265;25% of AUC of the parent or (2) if the metabolite is more polar than the parent drug and the AUC of metabolite is &#x02265; AUC of the parent drug&#x0201d;. In addition, a &#x0201c;lower cut-off value for the metabolite-to-parent AUC ratio may also be considered if a metabolite contains a structural alert for potential MBI&#x0201d; of CYP enzymes, since such inhibition carries a higher risk of causing drug interaction due to their prolonged inhibition effect.</p><p>Various computational approaches have been developed to assist with prioritization of drug candidates that have a low propensity for CYP inhibition. Most of QSAR models for enzyme inhibition are ligand-based <italic>in silico</italic> methods that predict the biological activities of drugs based on their 2D or 3D structures without knowing the 3D structure of the target protein or enzyme. Early QSAR models related reversible CYP inhibition of compounds to molecular properties such as octanol-water partition coefficient, polarizability, Taft steric parameter, and molecular volume (<xref rid="B27" ref-type="bibr">Hansch and Zhang, 1993</xref>; <xref rid="B20" ref-type="bibr">Gao and Hansch, 1996</xref>; <xref rid="B43" ref-type="bibr">Lewis et al., 2001</xref>; <xref rid="B26" ref-type="bibr">Hansch et al., 2004</xref>). However, subsequent 2D and 3D QSAR models included chemical structural descriptors. Examples of these models include CYP2D6 inhibition models using 26 aryloxypropanolamine compounds and CYP3A4 inhibition models (<xref rid="B50" ref-type="bibr">Roy and Roy, 2009</xref>). A similar approach was employed by Didziapetris et al. where baseline global QSAR models and local similarity-based corrections for over 800 compounds from various literature sources were used to predict CYP3A4 inhibition (<xref rid="B14" ref-type="bibr">Didziapetris et al., 2010</xref>). These models provide accuracies of 80%&#x02013;83% for the internal test set and 75%&#x02013;77% for the external test set. Among the most interesting findings from this study was that the presence of hydrophobic residues in a compound favored CYP3A4 inhibition while strong acidic or basic groups reduced inhibition probability. Another noticeable model was built by <xref rid="B7" ref-type="bibr">Cheng et al. (2011)</xref>, using a combination of classifiers to predict direct inhibition of 5 CYP enzymes. Although the dataset included over 24,700 compounds, compounds with IC<sub>50</sub> values in the range of 10&#x02013;57&#x000a0;&#x000b5;M have been classified as equivocal and were excluded to avoid uncertainty during model development, leaving 15,744 compounds for the training set. More recently, a model to predict inhibition or induction of 5 common CYP enzymes has been made available by <xref rid="B51" ref-type="bibr">Rudik et al. (2022)</xref>. These models calculated pIC<sub>50</sub> values (negative log of the IC50 value) and the largest training set consists of 16,997 compounds (5,702 positive). However, these models do not discriminate between RI and MBI.</p><p>In addition to traditional QSAR models, experimental screening methods have been employed to gain insight into CYP inhibition mechanisms. In a report by <xref rid="B23" ref-type="bibr">Gonzalez et al. (2021)</xref>, &#x0223c;5,000 compounds were screened for inhibition of CYP2C9, CYP2D6, and CYP3A4 using a luminescence-based cytochrome P450 assay. The resulting data were stratified in random forest and multi-task deep neural networks to construct QSAR models. A balanced accuracy of approximately 0.7 was achieved using the best model. Additionally, Veith et al., have screened 17,143 compounds against five recombinant CYP isozymes (1A2, 2C9, 2C19, 2D6 and 3A4) using an <italic>in vitro</italic> bioluminescent assay (<xref rid="B58" ref-type="bibr">Veith et al., 2009</xref>). Experimental data were used to interrogate inhibition activities of functional groups and molecular features. Finally, there have been molecular docking simulations, homology modeling, and molecular dynamics simulations of CYP enzymes that are outside of the scope of the current study.</p><p>Earlier QSAR models that relate CYP enzyme inhibition to molecular properties of inhibitors often use relatively small training sets which limits their applicability in a regulatory setting. More recent neural network models use larger datasets and offer higher accuracies compared to traditional models. However, they use a &#x0201c;black box&#x0201d; approach and therefore, identification of structural features responsible for the enzyme inhibition is challenging, if not impossible. As mentioned earlier, another critical shortcoming of most of the previous models is that they do not discriminate between RI and TDI. In addition, 3D-QSAR models are usually constructed under the assumption that the enzyme binding mode for all compounds is the same which may not be true (<xref rid="B15" ref-type="bibr">Ekins et al., 1999</xref>; <xref rid="B60" ref-type="bibr">Wang et al., 2000</xref>; <xref rid="B44" ref-type="bibr">Lu et al., 2001</xref>; <xref rid="B19" ref-type="bibr">Galetin et al., 2003</xref>; <xref rid="B16" ref-type="bibr">Ekroos and Sj&#x000f6;gren, 2006</xref>). Furthermore, some of QSAR models are proprietary and therefore cannot be assessed or reproduced due to unavailability of the training set data.</p><p>Due to these limitations, the present study focused on developing QSAR models using publicly available and chemically diverse data sets for TDI of CYP3A4 and RI of CYP3A4, CYP2C9, CYP2C19, and CYP2D6 enzymes. In addition, structural features that are responsible for enzyme inhibition have been identified. Overall, the newly constructed models can be used to identify molecular fragments that are responsible for CYP inhibition.</p></sec><sec sec-type="materials|methods" id="s2"><title>2 Materials and methods</title><sec id="s2-1"><title>2.1 QSAR model database</title><p>All training set data used to construct CYP inhibition QSAR models were comprised of non-proprietary data harvested from public data sources including BindingDB (<ext-link xlink:href="https://www.bindingdb.org/rwd/bind/index.jsp" ext-link-type="uri">www.bindingdb.org</ext-link>), Google Scholar, PubMed, and US Patents. All references are provided in the <xref rid="s12" ref-type="sec">Supplementary Table S1</xref>. RI data were collected for the four most common CYP enzymes, 3A4, 2C9, 2C19 and 2D6 and TDI data was harvested for 3A4. Although RI data were collected for CYP1A2, CYP2B6, and CYP2C8 as well as TDI data for CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2C19, the databases were small and did not yield viable models (data not shown).</p><p>The RI potential of a drug was measured using the concentration of the drug required to reduce the enzymatic activity of the enzyme towards its known substrate to half of its normal value, <italic>IC</italic>
<sub>
<italic>50</italic>
</sub>, or RI constant, <italic>K</italic>
<sub>
<italic>i</italic>
</sub>. However, the current FDA guidance recommends assessment of <italic>R</italic>
<sub>
<italic>1</italic>
</sub> using the following <xref rid="e1" ref-type="disp-formula">Equation 1</xref>:<disp-formula id="e1">
<mml:math id="m1" overflow="scroll"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">max</mml:mi><mml:mo>&#x02061;</mml:mo><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math>
<label>(1)</label>
</disp-formula>where <inline-formula id="inf1">
<mml:math id="m2" overflow="scroll"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">max</mml:mi><mml:mo>&#x02061;</mml:mo><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> is the maximal unbound plasma concentration of the interacting drug at steady state and <inline-formula id="inf2">
<mml:math id="m3" overflow="scroll"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> is the unbound inhibition constant determined <italic>in vitro</italic> (<ext-link xlink:href="http://www.fda.gov/media/134582/download" ext-link-type="uri">www.fda.gov/media/134582/download</ext-link>). In the present study, RI data were collected for <italic>IC</italic>
<sub>
<italic>50</italic>
</sub>, <italic>K</italic>
<sub>
<italic>i</italic>
</sub>, and <italic>R</italic>
<sub>
<italic>1</italic>
</sub> measurements, where available.</p><p>For irreversible inhibition, <italic>IC</italic>
<sub>
<italic>50</italic>
</sub> from direct inhibition is usually compared to the IC<sub>50</sub> after preincubation of the enzyme with a cofactor. A decrease in <italic>IC</italic>
<sub>
<italic>50</italic>
</sub> upon preincubation indicates TDI (<italic>i.e</italic>., IC<sub>50</sub> shift). Other common constants used in assessment of TDI were the maximal inactivation rate constant (<italic>k</italic>
<sub>
<italic>inact</italic>
</sub>), inactivator concentration that yields half of the maximum inactivation rate (<italic>K</italic>
<sub>
<italic>I</italic>
</sub>), and the first order rate constants for loss of CYP activity (<italic>k</italic>
<sub>
<italic>obs</italic>
</sub>) defined by the following <xref rid="e2" ref-type="disp-formula">Equation 2</xref> (<xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>):<disp-formula id="e2">
<mml:math id="m4" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math>
<label>(2)</label>
</disp-formula>where <inline-formula id="inf3">
<mml:math id="m5" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> is <inline-formula id="inf4">
<mml:math id="m6" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math>
</inline-formula> in the absence of the substrate, and <inline-formula id="inf5">
<mml:math id="m7" overflow="scroll"><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:math>
</inline-formula> is the concentration of the inactivator. In addition, the FDA guidance recommends assessment of <italic>R</italic>
<sub>
<italic>2</italic>
</sub>, which is defined as <xref rid="e3" ref-type="disp-formula">Equations 3</xref>, <xref rid="e4" ref-type="disp-formula">4</xref>:<disp-formula id="e3">
<mml:math id="m8" overflow="scroll"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="italic">deg</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="italic">deg</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:math>
<label>(3)</label>
</disp-formula>where<disp-formula id="e4">
<mml:math id="m9" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mn>50</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">max</mml:mi><mml:mo>&#x02061;</mml:mo><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>50</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi mathvariant="italic">max</mml:mi><mml:mo>&#x02061;</mml:mo><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math>
<label>(4)</label>
</disp-formula>and <inline-formula id="inf6">
<mml:math id="m10" overflow="scroll"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi mathvariant="italic">deg</mml:mi></mml:msub></mml:mrow></mml:math>
</inline-formula> is the apparent first-order degradation rate constant of the affected enzyme.</p><p>A binary scoring system was used for modeling purposes where a score of &#x0201c;1&#x0201d; was assigned to all chemicals classified as inhibitors or inactivators and &#x0201c;0&#x0201d; was used to denote non-inhibitor or non-inactivator. The experimental criteria used to classify CYP inhibition is presented below, in <xref rid="T1" ref-type="table">Table 1</xref>. The thresholds used to define reversible inhibition were obtained from available literature (<xref rid="B47" ref-type="bibr">Rao et al., 2000</xref>; <xref rid="B51" ref-type="bibr">Rudik et al., 2022</xref>), while the thresholds used for R<sub>1</sub>, IC<sub>50</sub> fold shift and R<sub>2</sub> were obtained from the FDA DDI guidance. Curated datasets are available in <xref rid="s12" ref-type="sec">Supplementary Table S1</xref>. Overall, there are 10,129 unique chemicals in the training sets.</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>Thresholds for identification of reversible and time-dependent inhibitors.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="2" align="center" colspan="1">Inhibition type</th><th align="left" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Classification</th></tr><tr><th align="center" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Inhibitor (scored as &#x0201c;1&#x0201d;)</th><th align="center" rowspan="1" colspan="1">Non- inhibitor (scored as &#x0201c;0&#x0201d;)</th></tr></thead><tbody valign="top"><tr><td rowspan="3" align="center" colspan="1">Reversible Inhibition (RI)</td><td align="center" rowspan="1" colspan="1">IC<sub>5o</sub> (&#x000b5;M)</td><td align="center" rowspan="1" colspan="1">&#x02264;10</td><td align="center" rowspan="1" colspan="1">&#x0003e;10</td></tr><tr><td align="center" rowspan="1" colspan="1">K<sub>i</sub> (&#x000b5;M)</td><td align="center" rowspan="1" colspan="1">&#x02264;10</td><td align="center" rowspan="1" colspan="1">&#x0003e;10</td></tr><tr><td align="center" rowspan="1" colspan="1">R<sub>1</sub>
</td><td align="center" rowspan="1" colspan="1">&#x02265;1.02</td><td align="center" rowspan="1" colspan="1">&#x0003c;1.02</td></tr><tr><td rowspan="4" align="center" colspan="1">Time dependent Inhibition (TDI)</td><td align="center" rowspan="1" colspan="1">IC<sub>50</sub> fold shift</td><td align="center" rowspan="1" colspan="1">&#x02265;1.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;1.5</td></tr><tr><td align="center" rowspan="1" colspan="1">Change in inhibition (%)</td><td align="center" rowspan="1" colspan="1">&#x02265;20</td><td align="center" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td align="center" rowspan="1" colspan="1">k<sub>obs</sub> (min<sup>-1</sup>)</td><td align="center" rowspan="1" colspan="1">&#x02265;0.01</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" rowspan="1" colspan="1">R<sub>2</sub>
</td><td align="center" rowspan="1" colspan="1">&#x02265;1.25</td><td align="center" rowspan="1" colspan="1">&#x0003c;1.25</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>2.2 Chemical structure curation</title><p>The chemical structures were obtained from BindingDB, SciFinder<sup>&#x000ae;</sup>, and PubChem databases in structure data file (SDF) format. Inorganic chemicals, noble gases, mixtures, single atoms, metals, and high molecular weight compounds (MW &#x02265; 1800) were excluded from the training set. For salts, the neutralized free forms were used. Manual inspection was performed to ensure the chemicals, their associated data and references were accurately recorded.</p></sec><sec id="s2-3"><title>2.3 SAR profiler literature curation</title><p>Structural features that are susceptible to bioactivation have been outlined in the literature, where collections of such features have been discussed and reviewed. In the present work, key publications (<xref rid="T2" ref-type="table">Table 2</xref>) have been analyzed to collate a set of structural features associated with bioactivation potentially leading to MBI of CYP enzymes. More specifically, a list of structural alerts associated with the formation of reactive metabolites was compiled together with the information on available evidence on their association with MBI including annotations on the proposed mechanisms underlying bioactivation and examples. These alerts were encoded into a Leadscope alert set to profile potential CYP inhibition and is referred to as the Structure-Activity Relationship (SAR) Profiler.</p><table-wrap position="float" id="T2"><label>TABLE 2</label><caption><p>Key publications that have been analyzed to collate structural alerts associated with bioactivation potentially leading to MBI of CYP enzymes.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Publication details</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Common substructures causing mechanism-based inactivation of cytochromes P450 (e.g., furans and thiophenes, dichloro- and trichloro-ethylenes)</td><td align="left" rowspan="1" colspan="1">
<xref rid="B18" ref-type="bibr">Fontana et al. (2005)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Diverse functional motifs used in drug-design that potentially undergo bioactivation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">Kalgutkar et al. (2005)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cytochrome P450 inhibition by different chemical classes</td><td align="left" rowspan="1" colspan="1">
<xref rid="B10" ref-type="bibr">Correia (2005)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Bioactivation potential of organic functional groups</td><td align="left" rowspan="1" colspan="1">
<xref rid="B39" ref-type="bibr">Kalgutkar and Soglia (2005)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Known structure-activity relationships for P450 inactivation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B38" ref-type="bibr">Kalgutkar et al. (2007)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">List of organic functional groups susceptible to bioactivation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">Kalgutkar (2008)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Analysis of drugs based on known structural alerts associated with bioactivation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B53" ref-type="bibr">Stepan et al. (2011)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Well-known toxicophores associated with bioactivation leading to reactive metabolite formation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B32" ref-type="bibr">Kalgutkar et al. (2012)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Functional groups associated with mechanism-based inactivation of CYP enzymes</td><td align="left" rowspan="1" colspan="1">
<xref rid="B46" ref-type="bibr">Orr et al. (2012)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Analysis of structural alerts associated with reactive metabolite formation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Kalgutkar and Dalvie (2015)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Structural alerts for P450 inactivation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B64" ref-type="bibr">Yu et al. (2015)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Analysis of the structural alert/reactive metabolite concept</td><td align="left" rowspan="1" colspan="1">
<xref rid="B34" ref-type="bibr">Kalgutkar (2020)</xref>
</td></tr></tbody></table></table-wrap><p>The analysis was also enriched with an additional literature search to complement the collected information especially on underlying bioactivation mechanisms (<xref rid="B4" ref-type="bibr">Bolleddula et al., 2014</xref>; <xref rid="B8" ref-type="bibr">Claesson and Minidis, 2018</xref>; <xref rid="B6" ref-type="bibr">Cerny et al., 2020</xref>; <xref rid="B36" ref-type="bibr">Kalgutkar and Driscoll, 2020</xref>; <xref rid="B65" ref-type="bibr">Zhang et al., 2020</xref>).</p></sec><sec id="s2-4"><title>2.4 Leadscope software</title><p>Leadscope Enterprise (LS) version 3.9 (Instem Inc., USA) was used to construct binary QSAR models. LS is a data mining, visualization, and advanced informatics application with the capability to build and apply 2D QSAR models. The software program was acquired and used under Research Collaboration Agreements between FDA/CDER and the software provider. All training set structures were imported into LS and fingerprinted using a set of 27,142 pre-defined medicinal chemistry structural features. A small predictive subset of these features was used to construct the model. Structural scaffolds were generated for the CYP inhibition models using the following criteria: 1) a minimum of three compounds per scaffold; 2) a minimum of six atoms per scaffold; 3) no restriction on the maximum number of rotatable bonds; and 4) a minimum absolute difference between the mean activity of the subset of compounds having that feature and the mean activity of the full set (<xref rid="B49" ref-type="bibr">Roberts et al., 2000</xref>). Molecular properties such as molecular weight, number of rotatable bonds, number of hydrogen bond donors, number of hydrogen bond acceptors, Lipinski score, AlogP (logarithm of 1-octanol/water partition coefficient), polar surface area, and atom count were calculated and used for building models.</p><p>Highly predictive features and the corresponding helper features were identified in the feature editor for retention while weakly predicted features were removed using Z-score, frequency, precision and mean activity as discriminating parameters (<xref rid="B49" ref-type="bibr">Roberts et al., 2000</xref>). Additional inspection was manually performed, and redundant or highly correlated features were removed.</p><p>For each model, cross-validation was performed 10 times using a 10% &#x000d7; 10% leave-many-out (LMO) method. This method randomly selects 10% of the training set for testing and reconstructs a reduced model using the remaining 90% of the compounds and recalculates the descriptor weights. This process was repeated 10 times to ensure that all the compounds present in the training set were predicted ten times. The average predicted values were used to generate a classic 2 &#x000d7; 2 contingency table containing counts of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN) and to evaluate predictive performance. Statistics such as sensitivity [TP/(TP + FN)], specificity [TN/(TN + FP)], positive predictivity [TP/(TP + FP)], negative predictivity [TN/(TN-FN)], and accuracy [(TP + TN)/(TP + TN + FP + FN)] were calculated as described by <xref rid="B67" ref-type="bibr">Cooper et al., 1979</xref>. Chemicals classified as out-of-domain (OOD) and equivocal were excluded from Cooper statistic calculations. Coverage was calculated as the percentage of all chemicals screened for which a prediction could be made (OOD results do not constitute a prediction).</p><p>A classification threshold was determined by varying the positive cutoff probability thresholds for equivocal results and analyzing the resulting Cooper statistics. The optimal probability range for indeterminate predictions for the models were identified to be 0.4 to 0.6. Predictions that are above the 0.6 probability cutoff were classified as positive, while predictions below 0.4 were classified as negative. A chemical was treated as OOD if it did not contain any structural model features or showed a lack of similarity to the training set compounds (at least 30% similarity to a single training set compound was required).</p><p>Additionally, structural features associated with MBI as proposed in the key publications (<xref rid="T2" ref-type="table">Table 2</xref>) were encoded in a preliminary version of a computerized expert-rule based profiler. Whereas the literature-based structural alerts are in general broadly defined and often liable to different interpretations, the computerized expert system had to specify all the details of the chemical environment associated with a given alerting chemical feature. A set of initial structural alerts were encoded and then subjected to a fingerprinting analysis. This methodology was developed to identify SAR knowledge across a series of proprietary chemicals databases containing relevant data without revealing any potentially confidential information on the individual chemicals (<xref rid="B1" ref-type="bibr">Ahlberg et al., 2016</xref>; <xref rid="B2" ref-type="bibr">Amberg et al., 2019</xref>). More specifically, the encoded structural alerts preliminarily defined from the literature curation were complemented with additional probing structural features (i.e., chemical features covering additional chemical space as implemented by Leadscope (<xref rid="B1" ref-type="bibr">Ahlberg et al., 2016</xref>)). The alerts and the additional features were matched against a proprietary database of chemicals where it was known whether a given chemical record was a CYP3A4 mechanism-based inhibitor or not. Such proprietary datasets were assembled by industry and made available to Leadscope through the fingerprinting analysis without disclosing the structures of the chemicals. Counts of the number of positive and negative hits (i.e., chemicals which are mechanism-based inhibitors and chemicals which are not mechanism-based inhibitors, respectively) from the proprietary database matching each substructure (i.e., the alerts and the additional features) were calculated using the Leadscope software. Each chemical feature (i.e., substructure) was then associated with a count of positives and negatives.</p><p>The results of the fingerprinting analysis were used to manually refine the structural alerts that were initially encoded from literature curation. This means that the resulting refined computerized expert-rule based profiler included a set of MBI alerts where the chemical environment of the alerts was manually revised based on the fingerprinting exercise as compared to the very general features defined in the literature. These alerts were then qualified using the 3A4 TDI dataset of 620 compounds. More specifically, each MBI alert was marked as predictive or indeterminate based on available evidence; an alert was marked as indeterminate if there were 3 or less examples from the CYP3A4 TDI dataset (i.e., chemicals from the CYP3A4 TDI dataset matching the alert of interest), or alert was evaluated not to be statistically significant (i.e., binomial distribution probability greater than 0.85). Expert review of the assignment was also carried out to revise it based on visual inspection of the chemicals in the CYP3A4 TDI dataset bearing the specific alert.</p></sec><sec id="s2-5"><title>2.5 External validation</title><p>The predictive performance of the CYP models was assessed using external validation sets comprised of approved drugs harvested from proprietary FDA applications and publicly available data sources including BindingDB (<ext-link xlink:href="https://www.bindingdb.org/rwd/bind/index.jsp" ext-link-type="uri">www.bindingdb.org</ext-link>), Google Scholar, PubMed, and US Patents. Similar to the training sets, the criteria in <xref rid="T1" ref-type="table">Table 1</xref> were used to classify the compounds in the validation sets. For consensus predictions using the SAR profiler and QSAR models, a positive prediction from the SAR profiler was used to justify an overall positive prediction when QSAR prediction was equivocal only.</p></sec></sec><sec sec-type="results" id="s3"><title>3 Results</title><sec id="s3-1"><title>3.1 Database overview</title><p>The final QSAR modeling database set contains 10,129 unique chemicals compiled from public sources. The number of chemicals in each individual set is shown in <xref rid="F1" ref-type="fig">Figure 1A</xref>. Each training set contains less inhibitors as compared to non-inhibitors with 38%, 34%, 28%, 32%, and 49% positive chemicals in CYP3A4 (RI), CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (TDI), respectively. <xref rid="F1" ref-type="fig">Figure 1B</xref> shows the number of chemicals present in one or more reversible CYP inhibition training sets. Overall, there are 151,058 chemicals present in all four RI datasets. Of these chemicals, 983 exhibit the same effect on all four CYP enzymes (with only 78 being inhibitors), reflecting the diversity of the binding sites of those enzymes. In addition, a total of 343 compounds were found to be in common between CYP3A4 RI and CYP3A4 TDI training sets (<xref rid="F1" ref-type="fig">Figure 1</xref>), showing 59% concordance.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>Database overview <bold>(A)</bold> Number of non-proprietary chemicals in each database. <bold>(B)</bold> Number of chemicals tested in one or more CYP enzyme. <bold>(C)</bold> Number of overlapping chemicals in the CYP3A4 (RI) and CYP3A4 (TDI) databases.</p></caption><graphic xlink:href="fphar-15-1451164-g001" position="float"/></fig><p>Additionally, proprietary data for CYP inhibition were harvested for a total of 231 approved drugs and 33 non-proprietary chemicals to use for external validation. The number of chemicals in each individual set is presented in <xref rid="F2" ref-type="fig">Figure 2A</xref>. A structure similarity analysis between the training and validation sets revealed that the external validation sets are 83%&#x02013;98% dissimilar when a similarity threshold of 70% is applied (<xref rid="F2" ref-type="fig">Figure 2B</xref>).</p><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>External validation database overview <bold>(A)</bold> Number of chemicals in each database. <bold>(B)</bold> Number of structurally similar (blue) and dissimilar (red) drugs in the external validation set when compared to the training set.</p></caption><graphic xlink:href="fphar-15-1451164-g002" position="float"/></fig></sec><sec id="s3-2"><title>3.2 Molecular descriptor analysis</title><p>The relationship between molecular descriptors and RI databases is presented in <xref rid="F3" ref-type="fig">Figure 3</xref>. As seen in previous studies (<xref rid="B42" ref-type="bibr">Lewis and Ito, 2010</xref>), CYP3A4 may be inhibited by large molecules, due to its large cavity size, when compared to other CYP enzymes as shown <xref rid="F3" ref-type="fig">Figure 3A</xref>. The molecular weight distribution of CYP3A4 inhibitors (positives) is also slightly higher than non-inhibitors (negatives, <xref rid="F3" ref-type="fig">Figure 3B</xref>). Another interesting finding is that CYP2D6 inhibitors are on average less polar than the rest of the enzymes, specifically CYP3A4 (<xref rid="F3" ref-type="fig">Figure 3C</xref>). Docking studies identify a hydrophobic binding pocket for CYP2D6 (<xref rid="B57" ref-type="bibr">VandenBrink et al., 2012</xref>), which is consistent with lower polar surface area (PSA) of its substrates (<xref rid="F3" ref-type="fig">Figure 3C</xref>). Similar trends were observed for validation sets, despite their small size (<xref rid="F3" ref-type="fig">Figures 3D&#x02013;F</xref>).</p><fig position="float" id="F3"><label>FIGURE 3</label><caption><p>Relationship between molecular descriptors and reversible CYP inhibition. <bold>(A, D)</bold> Normalized histograms for molecular weight of CYP inhibitors. <bold>(B, E)</bold> Molecular weight of CYP3A4 inhibitors (positives) compared to non-inhibitors (negatives). <bold>(C, F)</bold> Polar surface area (PSA) of reversible CYP inhibitors divided by their molecular weight. Panels A, B and C were generated using training sets and D, E, and F were generated using validation sets.</p></caption><graphic xlink:href="fphar-15-1451164-g003" position="float"/></fig></sec><sec id="s3-3"><title>3.3 Development of QSAR models</title><p>In the present study, two modeling approaches were utilized to construct RI and TDI QSAR models. The CYP3A4 TDI models were constructed using a single model approach, while reversible CYP inhibition models were constructed using average-modeling approach to obtain an optimal active-to-inactive ratio. For the average-modeling approach, submodels were created using subsets of the training set with optimal active-to-inactive ratio such that all of the compounds are present in at least one submodel. When the average model is applied, each submodel predicts a value, and the average of all of the predicted values is reported. The final models contained a total of 524, 545, 682, 592 and 361 features in the CYP3A4 (RI), CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (TDI), respectively. The structural features with highest Z-scores for each individual model is presented in <xref rid="T3" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="T3"><label>TABLE 3</label><caption><p>Top structural features for CYP inhibition.</p></caption><table frame="hsides" rules="groups"><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">CYP3A4</td><td colspan="2" align="center" rowspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx1.jpg"/> toluene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx2.jpg"/>
<break/>
<italic>N</italic>-ethyllformamide</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx3.jpg"/>
<break/>Amino arylmethane</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx4.jpg"/>
<break/>
<italic>N</italic>-phenethylformamide</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx5.jpg"/> carbamate</td></tr><tr><td rowspan="2" align="left" colspan="1"/><td align="right" rowspan="1" colspan="1">Z-Score</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="right" rowspan="1" colspan="1">Frequency</td><td align="center" rowspan="1" colspan="1">3,185</td><td align="center" rowspan="1" colspan="1">311</td><td align="center" rowspan="1" colspan="1">1,561</td><td align="center" rowspan="1" colspan="1">288</td><td align="center" rowspan="1" colspan="1">204</td></tr><tr><td align="center" rowspan="1" colspan="1">CYP2C9</td><td colspan="2" align="center" rowspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx6.jpg"/> aryl-arylamino ethane</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx7.jpg"/> sulfonylbenzene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx8.jpg"/>
<break/>Aminomethyl-benzene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx9.jpg"/>
<break/>Aryl-aminomethyl-benzene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx10.jpg"/> sulfonyl</td></tr><tr><td rowspan="2" align="left" colspan="1"/><td align="right" rowspan="1" colspan="1">Z-Score</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="right" rowspan="1" colspan="1">Frequency</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">586</td><td align="center" rowspan="1" colspan="1">476</td><td align="center" rowspan="1" colspan="1">133</td><td align="center" rowspan="1" colspan="1">799</td></tr><tr><td align="center" rowspan="1" colspan="1">CYP2C19</td><td colspan="2" align="center" rowspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx11.jpg"/> aryl-arylamino ethane</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx12.jpg"/>
<break/>3-vinyl-1<italic>H</italic>-indazole</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx13.jpg"/>
<break/>6-alkyl-1<italic>H</italic>-indazole</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx14.jpg"/> alkylperoxide</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx15.jpg"/> amino arylmethane</td></tr><tr><td rowspan="2" align="left" colspan="1"/><td align="center" rowspan="1" colspan="1">Z-Score</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="center" rowspan="1" colspan="1">Frequency</td><td align="center" rowspan="1" colspan="1">137</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">546</td></tr><tr><td align="center" rowspan="1" colspan="1">CYP2D6</td><td colspan="2" align="center" rowspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx16.jpg"/>
<break/>Aminomethyl-benzene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx17.jpg"/>
<break/>secondary alkylamine</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx18.jpg"/>
<break/>Amino-arylethane</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx19.jpg"/>
<break/>secondary amine</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx20.jpg"/>
<break/>Alkyl-aminomethyl-benzene</td></tr><tr><td rowspan="2" align="left" colspan="1"/><td align="center" rowspan="1" colspan="1">Z-Score</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="center" rowspan="1" colspan="1">Frequency</td><td align="center" rowspan="1" colspan="1">864</td><td align="center" rowspan="1" colspan="1">1,143</td><td align="center" rowspan="1" colspan="1">312</td><td align="center" rowspan="1" colspan="1">1,324</td><td align="center" rowspan="1" colspan="1">673</td></tr><tr><td align="center" rowspan="1" colspan="1">CYP3A4 TDI</td><td colspan="2" align="center" rowspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx21.jpg"/> alkyl halobenzene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx22.jpg"/>
<break/>Alkoxy-4-alkylbenzene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx23.jpg"/>
<break/>Alkoxy-4-(oxopropyl)-benzene</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx24.jpg"/>
<break/>1,2-diphenoxyethane</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx25.jpg"/>
<break/>
<italic>N</italic>-cyclopropyl-<italic>N</italic>-methylforamide</td></tr><tr><td rowspan="2" align="left" colspan="1"/><td align="right" rowspan="1" colspan="1">Z-Score</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="right" rowspan="1" colspan="1">Frequency</td><td align="center" rowspan="1" colspan="1">114</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">57</td></tr></tbody></table></table-wrap></sec><sec id="s3-4"><title>3.4 Development of SAR profiler for MBI</title><p>The literature analysis and the fingerprinting exercise led to the definition of 58 MBI structural alerts (see <xref rid="s12" ref-type="sec">Supplementary Table S2</xref> for the complete list of alerts). Each alert is built using different rules covering a specific chemical environment to identify potential reactive metabolites leading to the irreversible (or quasi-irreversible) inhibition of CYPs.</p><p>The qualification of the structural alerts was conducted using the 3A4 TDI dataset and the statistical analysis (see Methods section, Structural alerts) led to the definition of a selection of alerts as being predictive. These alerts are listed in <xref rid="T4" ref-type="table">Table 4</xref>.</p><table-wrap position="float" id="T4"><label>TABLE 4</label><caption><p>MBI alerts qualified as statistically significant and predictive (based on the number of examples matching the alert).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th colspan="2" align="center" rowspan="1">Name</th><th align="center" rowspan="1" colspan="1">General representation of the structural alert</th><th align="left" rowspan="1" colspan="1">Description</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="center" rowspan="1">Benzodioxoles (methylenedioxyphenyl compounds)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx26.jpg"/>
<break/>No substitution in C8</td><td align="left" rowspan="1" colspan="1">The benzodioxole moiety is included in the literature list of the main substructures causing MBI of cytochrome P450 (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B18" ref-type="bibr">Fontana et al., 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>; <xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>)<break/>Time-dependent inhibition of P450 by benzodioxole derivatives is proposed to involve P450 oxidation of the methylenedioxy ring carbon to a carbene intermediate (<xref rid="B39" ref-type="bibr">Kalgutkar and Soglia, 2005</xref>; <xref rid="B32" ref-type="bibr">Kalgutkar et al., 2012</xref>). This reactive metabolite may inhibit the enzyme by strongly coordinating to heme iron in the active site of P450 (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>). An alternative pathway leading to MBI may also involve the formation of the o-quinone intermediates then binding to the P450 active site residues (<xref rid="B32" ref-type="bibr">Kalgutkar et al., 2012</xref>; <xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Furans</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx27.jpg"/>
</td><td align="left" rowspan="1" colspan="1">The furan moiety is included in the literature list of the main substructures causing MBI of cytochrome P450 (<xref rid="B18" ref-type="bibr">Fontana et al., 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>; <xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>). MBI is associated with the formation of an epoxide intermediate that is susceptible to nucleophilic attack by nitrogen atoms of the CYP&#x02019;s protein residues or of the CYP&#x02019;s heme group. Formation of a covalent bond between the reactive metabolite and P450 results in inactivation of the enzyme (<xref rid="B18" ref-type="bibr">Fontana et al., 2005</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Terminal (omega and omega-1) alkynes</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx28.jpg"/>or<break/>
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx29.jpg"/> (R = carbon substitution)</td><td align="left" rowspan="1" colspan="1">Alkynes are in general included in the list of the main substructures causing MBI of cytochrome P450 (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B18" ref-type="bibr">Fontana et al., 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>; <xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>). The omega and omega-1 alkynes (terminal) are also specifically discussed as MBI structural alerts (36). The position of the triple bond seems to affect the bioactivation pathway and the type of reactive metabolites that may alkylate the heme prosthetic group or the apoprotein (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>). It was noted that terminal acetylenes (RC&#x02261;H) form covalent adducts with the P450 heme group (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>)</td></tr><tr><td colspan="2" align="center" rowspan="1">Primary amines (non-aromatic)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx30.jpg"/>
<break/>R = alkyl carbon (No additional substituents bound to N)</td><td align="left" rowspan="1" colspan="1">Primary amines are known to be quasi-irreversible CYP inactivators (<xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>). In general, alkyl amines may cause MBI of cytochrome P450 and they are responsible for the majority of clinical drug-drug interactions (<xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>). More specifically, amines can be oxidized and coordinate the heme iron inhibiting P450 (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>). It is suggested that primary amines are first hydroxylated to hydroxylamines, and these can undergo further oxidation to a nitroso species, which can then coordinate the heme iron (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Secondary cyclic amines (non-aromatic)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx31.jpg"/>
<break/>R<sub>1</sub>, R<sub>2</sub> = alkyl carbon<break/>R<sub>1</sub>-N-R<sub>2</sub> are part of a cycle</td><td align="left" rowspan="1" colspan="1">In general, alkyl amines may cause MBI of cytochrome P450 (<xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>). More specifically, amines can form intermediates following oxidation and after this they can coordinate the heme iron and inhibit P450 (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>). However, primary amines are required for the formation of the metal complex causing quasi-irreversible inhibition of P450 (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>). Indeed, secondary cyclic amines are considered to alert for the formation of reactive metabolites via a nitroxide radical (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Cyclopropylamines</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx32.jpg"/>
<break/>R<sub>1</sub>, R<sub>2</sub> = H or carbon with no heteroatom attachement</td><td align="left" rowspan="1" colspan="1">Cyclopropylamines are well-known substructures causing MBI of cytochrome P450 (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>). A bioactivation pathway of cyclopropylamines has not been fully elucidated. MBI is proposed to occur via covalent binding to the P450 active site or apoprotein (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>; <xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>). Cyclopropylamines with or without an abstractable alpha-carbon hydrogen can inactivate P450; cyclopropylanilines are reported not to inhibit P450 activity (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Hydroquinone (ortho and para) derivatives</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx33.jpg"/>
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx34.jpg"/>
<break/>R<sub>1</sub>, R<sub>2</sub> = H or saturated carbon<break/>
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx35.jpg"/>
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx36.jpg"/>
</td><td align="left" rowspan="1" colspan="1">Phenols are generally included in the list of the main substructures causing MBI of cytochrome P450 (<xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>). Following bioactivation of phenols, quinone intermediates and/or epoxides may be formed which are likely associated with MBI (<xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Epoxides</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx37.jpg"/>
</td><td align="left" rowspan="1" colspan="1">The epoxide moiety is included in the list of the main substructures causing MBI of cytochrome P450 (<xref rid="B18" ref-type="bibr">Fontana et al., 2005</xref>). They are electrophilic functional groups that can then directly react with nucleophiles contained in the biological macromolecules (<xref rid="B32" ref-type="bibr">Kalgutkar et al., 2012</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Piperazines (tertiary amines)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx38.jpg"/>
</td><td align="left" rowspan="1" colspan="1">Piperazines are not explicitly mentioned in the literature as alerts for MBI of cytochrome P450. Bioactivation of the piperazine ring is mediated by P450 or monoamine oxidase, which catalyze reactions such as <italic>N</italic>-dealkylation, ring hydroxylation, <italic>N</italic>-oxygenation, and ring opening (<xref rid="B4" ref-type="bibr">Bolleddula et al., 2014</xref>). Bioactivation is proposed to involve hydroxylation at the alpha- or beta- carbon atom forming an unstable carbinolamine intermediate; This then leads to the formation of amino aldehyde and an iminium ion/imine that are reactive electrophile intermediates and that can covalently bind to nucleophiles contained in biological macromolecules (<xref rid="B4" ref-type="bibr">Bolleddula et al., 2014</xref>). For compounds containing the phenyl piperazine system, bioactivation may also occur via formation of a quinone-imine intermediate. This is formed following hydroxylation of the phenyl ring (<xref rid="B4" ref-type="bibr">Bolleddula et al., 2014</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Alkylphenols (ortho- and para), quinone-methide precursors</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx39.jpg"/>
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx40.jpg"/>
<break/>R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>: H or C</td><td align="left" rowspan="1" colspan="1">In general, the phenol moiety is included in the list of the main substructures causing MBI of cytochrome P450 (<xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>). Bioactivation of alkylphenols may lead to the formation of the reactive quinone-methide species (<xref rid="B39" ref-type="bibr">Kalgutkar and Soglia, 2005</xref>) causing apoprotein arylation in P450 (<xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Alkylaromatic ethers (ortho- and para), quinone-methide precursors</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx41.jpg"/>
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx42.jpg"/>
<break/>R<sub>1</sub>, R<sub>2</sub>: saturated carbon</td><td align="left" rowspan="1" colspan="1">Alkylaromatic ethers are not explicitly mentioned in the literature as alerts for MBI of cytochrome P450. Notably, the P450-mediated oxidative <italic>O</italic>-dealkylation reactions of <italic>o</italic>- or <italic>p</italic>-alkylaromatic ethers may form the corresponding phenols (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>). Formation of reactive quinone-methide species can then occur (<xref rid="B39" ref-type="bibr">Kalgutkar and Soglia, 2005</xref>) causing apoprotein arylation in P450 (<xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Reactive arenes</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx43.jpg"/>
<break/>R<sub>1</sub>, R<sub>2</sub> = H or C<break/>
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx44.jpg"/>
<break/>C9: no heteroatom attachment<break/>C7: saturated carbon</td><td align="left" rowspan="1" colspan="1">Arenes may potentially lead to reactive metabolites (i.e., arene oxides) upon epoxidation (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>; <xref rid="B39" ref-type="bibr">Kalgutkar and Soglia, 2005</xref>). This specific alert identifies specific chemical environments containing the arene substructure and other moieties that are mentioned in the literature as being associated with MBI: alkyl amines (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B38" ref-type="bibr">Kalgutkar et al., 2007</xref>; <xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>) and alkenes (<xref rid="B10" ref-type="bibr">Correia, 2005</xref>; <xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B64" ref-type="bibr">Yu et al., 2015</xref>)</td></tr><tr><td colspan="2" align="left" rowspan="1">Arenes (miscellaneous)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2024-1451164_wc_tfx45.jpg"/>
<break/>Bonds in the heteroaromatic rings can be of various types (e.g., single, double)</td><td align="left" rowspan="1" colspan="1">Arenes may potentially lead to reactive metabolites (i.e., arene oxides) upon epoxidation (<xref rid="B37" ref-type="bibr">Kalgutkar et al., 2005</xref>; <xref rid="B39" ref-type="bibr">Kalgutkar and Soglia, 2005</xref>). This specific alert identifies benzopyran analogues</td></tr></tbody></table></table-wrap></sec><sec id="s3-5"><title>3.5 Predictive performance of QSAR models and SAR profiler</title><p>The predictive performance statistics of CYP inhibition models using cross validation experiments and external validation experiments are presented in <xref rid="T5" ref-type="table">Table 5</xref>. Overall, the models offer 78%&#x02013;84% sensitivity and 79%&#x02013;84% negative predictivity in cross-validation. Concordance of the cross-validation and the external validation of the models range from 79% to 83% and from 66 to 86, respectively. Unlike training sets, the external validation sets are almost exclusively made of drugs. The difference in chemical space between the two databases (<xref rid="F2" ref-type="fig">Figure 2</xref> External validation database overview (A) Number of chemicals in each database. (B)) may explain relatively lower sensitivities for external validations. Additional validation studies were carried out to determine the optimal approach to combine CYP3A4 (MBI) predictions from SAR profiler and QSAR. <xref rid="T5" ref-type="table">Table 5</xref> shows the performance statistics when a SAR profiler prediction is used to justify an overall positive or negative prediction only in cases where a QSAR prediction was equivocal.</p><table-wrap position="float" id="T5"><label>TABLE 5</label><caption><p>Statistical performance of CYP inhibition models.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="2" align="center" colspan="1">Model</th><th colspan="5" align="center" rowspan="1">Cross-validation</th><th colspan="7" align="center" rowspan="1">External validation</th></tr><tr><th align="center" rowspan="1" colspan="1">3A4 QSAR</th><th align="center" rowspan="1" colspan="1">2C9 QSAR</th><th align="center" rowspan="1" colspan="1">2C19 QSAR</th><th align="center" rowspan="1" colspan="1">2D6 QSAR</th><th align="center" rowspan="1" colspan="1">3A4 (TDI) QSAR</th><th align="center" rowspan="1" colspan="1">3A4 QSAR</th><th align="center" rowspan="1" colspan="1">2C9 QSAR</th><th align="center" rowspan="1" colspan="1">2C19 QSAR</th><th align="center" rowspan="1" colspan="1">2D6 QSAR</th><th align="center" rowspan="1" colspan="1">3A4 (TDI) QSAR</th><th align="center" rowspan="1" colspan="1">3A4 SAR profiler</th><th align="center" rowspan="1" colspan="1">SAR profiler and 3A4 (TDI) QSAR</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Sensitivity (%)</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">63</td></tr><tr><td align="center" rowspan="1" colspan="1">Specificity (%)</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">74</td></tr><tr><td align="center" rowspan="1" colspan="1">Pos Pred<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref> (%)</td><td align="center" rowspan="1" colspan="1">69 (79)</td><td align="center" rowspan="1" colspan="1">65 (78)</td><td align="center" rowspan="1" colspan="1">61 (80)</td><td align="center" rowspan="1" colspan="1">69 (82)</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">30 (65)</td><td align="center" rowspan="1" colspan="1">38 (80)</td><td align="center" rowspan="1" colspan="1">19 (72)</td><td align="center" rowspan="1" colspan="1">38 (83)</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">79</td></tr><tr><td align="center" rowspan="1" colspan="1">Neg Pred<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>(%)</td><td align="center" rowspan="1" colspan="1">86 (79)</td><td align="center" rowspan="1" colspan="1">89 (81)</td><td align="center" rowspan="1" colspan="1">93 (84)</td><td align="center" rowspan="1" colspan="1">92 (84)</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">88 (64)</td><td align="center" rowspan="1" colspan="1">93 (67)</td><td align="center" rowspan="1" colspan="1">97 (73)</td><td align="center" rowspan="1" colspan="1">97 (80)</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">56</td></tr><tr><td align="center" rowspan="1" colspan="1">Concordance (%)</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">67</td></tr><tr><td align="center" rowspan="1" colspan="1">Coverage (%)</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">72</td></tr><tr><td align="center" rowspan="1" colspan="1">Chi-squared</td><td align="center" rowspan="1" colspan="1">1760</td><td align="center" rowspan="1" colspan="1">1,123</td><td align="center" rowspan="1" colspan="1">833</td><td align="center" rowspan="1" colspan="1">1719</td><td align="center" rowspan="1" colspan="1">206</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">10</td></tr></tbody></table><table-wrap-foot><fn id="Tfn1"><label>
<sup>a</sup>
</label><p>Numbers in parentheses show normalized predictivity.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="s4"><title>4 Discussion</title><p>(Q)SAR models have been proven to be particularly useful for rapid screening of drug candidates during drug development. Additionally, they are used in a regulatory environment to provide rapid assessment of toxicological and pharmacological properties. Models that generate interpretable predictions are more desirable by regulators as supporting evidence on the relevance of a prediction can be more easily interrogated. Furthermore, application of complementary models has been proven to be successful in supporting the International Council on Harmonization (ICH) M7 guidance (<xref rid="B41" ref-type="bibr">Landry et al., 2019</xref>). In the present study, two modeling techniques have been utilized to construct CYP inhibition models. These models can facilitate identification of structural alerts and help determine whether a metabolite is to be investigated in reversible and time-dependent <italic>in vitro</italic> studies under the DDI guidance (<xref rid="B54" ref-type="bibr">Sudsakorn et al., 2020</xref>).</p><sec id="s4-1"><title>4.1 Interpretability of structural alerts</title><p>In contrast to &#x0201c;black box&#x0201d; models, the current work identifies molecular features responsible for CYP enzyme inhibition of drugs and other small molecules. As seen in <xref rid="T3" ref-type="table">Table 3</xref>, planar aromatic rings and secondary amines are among the top reversible inhibitory alerts for all CYPs. Earlier studies found that strong binding properties of amines and nitrogen-containing, heterocyclic derivatives intensify their inhibitory activities (<xref rid="B56" ref-type="bibr">Testa and Jenner, 1981</xref>). In addition, scaffolds containing oxygen or sulfur atoms attract iron cation of cytochrome P-450 through electronic interactions, resulting in 6-coordinated complexes (<xref rid="B56" ref-type="bibr">Testa and Jenner, 1981</xref>).</p><p>The presence of aromatic rings among top structural alerts for CYP3A4 inhibition may be due to pi&#x02013;pi stacking interactions between those rings and phenylalanine residues uniquely present in the CYP3A4 (<xref rid="B3" ref-type="bibr">Beck et al., 2021</xref>). Also, the presence of flexible backbones allows a ligand to better fit into the active site of CYP3A4 (<xref rid="B40" ref-type="bibr">Kaur et al., 2016</xref>). That may explain the top linear structural alerts for CYP3A4 inhibition.</p><p>All top features for CYP2D6 have amine groups, in agreement with previous findings (<xref rid="B52" ref-type="bibr">Sridhar et al., 2012</xref>). The active site of CYP2D6 contains two carboxylic acids from Q216 and D301 that are involved in substrate recognition and binding (<xref rid="B12" ref-type="bibr">de Groot et al., 2009</xref>; <xref rid="B59" ref-type="bibr">Wang et al., 2009</xref>). These acidic residues interact with primary and secondary amines present in the inhibitors (<xref rid="B3" ref-type="bibr">Beck et al., 2021</xref>). The presence of a basic nitrogen atom and a planar aromatic ring in many of CYP2D6 substrates has been reported before (<xref rid="B63" ref-type="bibr">Yu et al., 2004</xref>; <xref rid="B21" ref-type="bibr">Gay et al., 2010</xref>). Furthermore, aromatic rings in inhibitors may interact with F120 and F483 through pi&#x02013;pi stacking (<xref rid="B3" ref-type="bibr">Beck et al., 2021</xref>).</p><p>The presence of an amine residue has been proposed to favor substrate binding to CYP2C9 through electrostatic interactions (<xref rid="B31" ref-type="bibr">Jones et al., 1996</xref>). Heterocycles and heterocyclic nitrogen atoms that are frequently seen in CYP2C19 inhibitors coordinate with Heme-501 (<xref rid="B3" ref-type="bibr">Beck et al., 2021</xref>). Also, numerous pi&#x02013;pi stacking interactions occur between small-molecule arylene groups and F114 and F476 in CYP2C19 (<xref rid="B3" ref-type="bibr">Beck et al., 2021</xref>). Similar pi&#x02013;pi stacking interactions are observed in CYP2C9.</p><p>On the other hand, tertiary aromatic amines such as pyridine are among features with lowest Z-scores for all models. Carboxylic acid is in the bottom of the list for CYP3A4 (both RI and TDI) and CYP2D6.</p><p>Among structural features for CYP3A4 TDI, cyclopropylamine is reported to cause mechanism-based inhibition of CYP enzymes through heme alkylation (<xref rid="B46" ref-type="bibr">Orr et al., 2012</xref>; <xref rid="B30" ref-type="bibr">Hoemann et al., 2016</xref>; <xref rid="B62" ref-type="bibr">Xu et al., 2022</xref>). Experiments show that pyridine is a weak inactivator of CYP3A4 due to the weak ligation of its nitrogen to the heme iron (<xref rid="B40" ref-type="bibr">Kaur et al., 2016</xref>).</p><p>Among 58 MBI alerts obtained from literature, 24 alerts are similar to, or exact matches of the alerts identified by the QSAR model. Cyclopropyl amines, hydroquinone derivatives, alkoxy benzenes, and heteroaromatic rings are the overlapping alerts that cover the largest subset of compounds in the TDI training set with up to 253 common compounds in the training set.</p><p>These results suggest that the two modeling techniques can be used in combination to obtain additional weight of evidence for the MBI predictions.</p></sec><sec id="s4-2"><title>4.2 Practical application</title><p>An external validation set was used to evaluate the predictive performance of the RI QSAR models and to determine the optimal approach for combining predictions from the current SAR profiler for MBI and QSAR model for CYP3A4 TDI. Previous studies showed that using multiple (Q)SAR models in combination can increase the sensitivity when a positive prediction from any one system is used to justify an overall positive prediction (<xref rid="B29" ref-type="bibr">Hillebrecht et al., 2011</xref>; <xref rid="B9" ref-type="bibr">Contrera, 2013</xref>; <xref rid="B55" ref-type="bibr">Sutter et al., 2013</xref>; <xref rid="B17" ref-type="bibr">Faramarzi et al., 2022</xref>). However, it should be noted that the SAR profiler has been constructed to provide information on potential mechanisms of inhibition for all CYP enzymes while the QSAR model and the external validation set are both based only on the CYP3A4 TDI data. As such, the rules for using two methodologies in combination have been adjusted. Overall, it was found that the SAR profiler identified additional positive signals related to other CYP enzymes and therefore showed high sensitivity and low specificity in the external validation. However, in the cases where an equivocal prediction was generated by the CYP3A4 TDI QSAR model, a positive prediction from the SAR Profiler provides additional mechanistic information to determine the relevance of the positive and negative features obtained from the QSAR model prediction. Moreover, it was determined that sensitivity can be increased to 69% (<xref rid="T5" ref-type="table">Table 5</xref>) without drastically decreasing specificity when a positive prediction from the SAR profiler is used to justify an overall positive prediction when the QSAR prediction was equivocal.</p></sec></sec><sec sec-type="conclusion" id="s5"><title>5 Conclusion</title><p>In the present study, an extensive literature search was performed and alerts for mechanism-based inhibition of CYPs were collected and used to develop a SAR profiler. Furthermore, five quantitative structure-activity relationship (QSAR) models were constructed to predict not only time-dependent inhibition of the major drug-metabolizing enzyme, CYP3A4, but also reversible inhibition of CYPs 3A4, 2C9, 2C19 and 2D6. Structural alerts identified by these QSAR models and the SAR profiler were compared and although some overlap was identified, each model was found to contain additional information. Lastly, an optimal method for combining predictions from the different methodologies was determined. These new models provide a faster and more effective evaluation of CYP inhibition potential and may be used to support of DDI structural alert identification.</p></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref rid="s12" ref-type="sec">Supplementary Material</xref>.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>SF: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Writing&#x02013;original draft. AB: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing&#x02013;original draft. KC: Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Writing&#x02013;review and editing. XY: Data curation, Supervision, Validation, Writing&#x02013;review and editing. GM: Conceptualization, Formal Analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing&#x02013;review and editing. DV: Data curation, Supervision, Writing&#x02013;review and editing. LS: Conceptualization, Formal Analysis, Funding acquisition, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing&#x02013;original draft, Writing&#x02013;review and editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>Authors AB, KC, and GM were employed by Instem Inc.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="disclaimer" id="s11"><title>Author Disclaimer</title><p>This article reflects the views of the authors and should not be construed to represent FDA&#x02019;s views or policies. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services.</p></sec><sec id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2024.1451164/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2024.1451164/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="DataSheet1.zip"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahlberg</surname><given-names>E.</given-names></name><name><surname>Amberg</surname><given-names>A.</given-names></name><name><surname>Beilke</surname><given-names>L. D.</given-names></name><name><surname>Bower</surname><given-names>D.</given-names></name><name><surname>Cross</surname><given-names>K. P.</given-names></name><name><surname>Custer</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: a case study using aromatic amine mutagenicity</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<volume>77</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2016.02.003</pub-id>
<pub-id pub-id-type="pmid">26879463</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amberg</surname><given-names>A.</given-names></name><name><surname>Anger</surname><given-names>L. T.</given-names></name><name><surname>Bercu</surname><given-names>J.</given-names></name><name><surname>Bower</surname><given-names>D.</given-names></name><name><surname>Cross</surname><given-names>K. P.</given-names></name><name><surname>Custer</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?</article-title>
<source>Mutagenesis</source>
<volume>34</volume>, <fpage>67</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1093/mutage/gey020</pub-id>
<pub-id pub-id-type="pmid">30189015</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beck</surname><given-names>T. C.</given-names></name><name><surname>Beck</surname><given-names>K. R.</given-names></name><name><surname>Morningstar</surname><given-names>J.</given-names></name><name><surname>Benjamin</surname><given-names>M. M.</given-names></name><name><surname>Norris</surname><given-names>R. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Descriptors of cytochrome inhibitors and useful machine learning based methods for the design of safer drugs</article-title>. <source>Pharm. (Basel)</source>
<volume>14</volume>, <fpage>472</fpage>. <pub-id pub-id-type="doi">10.3390/ph14050472</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bolleddula</surname><given-names>J.</given-names></name><name><surname>Dement</surname><given-names>K.</given-names></name><name><surname>Driscoll</surname><given-names>J. P.</given-names></name><name><surname>Worboys</surname><given-names>P.</given-names></name><name><surname>Brassil</surname><given-names>P. J.</given-names></name><name><surname>Bourdet</surname><given-names>D. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</article-title>. <source>Drug Metab. Rev.</source>
<volume>46</volume>, <fpage>379</fpage>&#x02013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.3109/03602532.2014.924962</pub-id>
<pub-id pub-id-type="pmid">24909234</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borda</surname><given-names>I. T.</given-names></name><name><surname>Slone</surname><given-names>D.</given-names></name><name><surname>Jick</surname><given-names>H.</given-names></name></person-group> (<year>1968</year>). <article-title>Assessment of adverse reactions within a drug surveillance program</article-title>. <source>Jama</source>
<volume>205</volume>, <fpage>645</fpage>&#x02013;<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1968.03140350055016</pub-id>
<pub-id pub-id-type="pmid">5695107</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cerny</surname><given-names>M. A.</given-names></name><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><name><surname>Obach</surname><given-names>R. S.</given-names></name><name><surname>Sharma</surname><given-names>R.</given-names></name><name><surname>Spracklin</surname><given-names>D. K.</given-names></name><name><surname>Walker</surname><given-names>G. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Effective application of metabolite profiling in drug design and discovery</article-title>. <source>J. Med. Chem.</source>
<volume>63</volume>, <fpage>6387</fpage>&#x02013;<lpage>6406</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01840</pub-id>
<pub-id pub-id-type="pmid">32097005</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers</article-title>. <source>J. Chem. Inf. Model.</source>
<volume>51</volume>, <fpage>996</fpage>&#x02013;<lpage>1011</lpage>. <pub-id pub-id-type="doi">10.1021/ci200028n</pub-id>
<pub-id pub-id-type="pmid">21491913</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Claesson</surname><given-names>A.</given-names></name><name><surname>Minidis</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Systematic approach to organizing structural alerts for reactive metabolite formation from potential drugs</article-title>. <source>Chem. Res. Toxicol.</source>
<volume>31</volume>, <fpage>389</fpage>&#x02013;<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.8b00046</pub-id>
<pub-id pub-id-type="pmid">29746101</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Contrera</surname><given-names>J. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Validation of Toxtree and SciQSAR <italic>in silico</italic> predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticals</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<volume>67</volume>, <fpage>285</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2013.08.008</pub-id>
<pub-id pub-id-type="pmid">23969001</pub-id>
</mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooper</surname><given-names>J. A. 2nd</given-names></name><name><surname>Saracci</surname><given-names>R.</given-names></name><name><surname>Cole</surname><given-names>P.</given-names></name></person-group> (<year>1979</year>). <article-title>Describing the validity of carcinogen screening tests</article-title>. <source>Br. J. Canc.</source>
<volume>39</volume>, <fpage>87</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.1979.10</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Correia</surname><given-names>M. A.</given-names></name></person-group> (<year>2005</year>). <source>Cytochrome P450: structure, mechanism, and biochemistry</source>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>. <comment>Imprint: Springer, 2015</comment>.</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Costa</surname><given-names>A. J.</given-names></name></person-group> (<year>1991</year>). <article-title>Potential drug interactions in an ambulatory geriatric population</article-title>. <source>Fam. Pract.</source>
<volume>8</volume>, <fpage>234</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1093/fampra/8.3.234</pub-id>
<pub-id pub-id-type="pmid">1822974</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Groot</surname><given-names>M. J.</given-names></name><name><surname>Wakenhut</surname><given-names>F.</given-names></name><name><surname>Whitlock</surname><given-names>G.</given-names></name><name><surname>Hyland</surname><given-names>R.</given-names></name></person-group> (<year>2009</year>). <article-title>Understanding CYP2D6 interactions</article-title>. <source>Drug Discov. Today</source>
<volume>14</volume>, <fpage>964</fpage>&#x02013;<lpage>972</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2009.07.005</pub-id>
<pub-id pub-id-type="pmid">19638317</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deodhar</surname><given-names>M.</given-names></name><name><surname>Al Rihani</surname><given-names>S. B.</given-names></name><name><surname>Arwood</surname><given-names>M. J.</given-names></name><name><surname>Darakjian</surname><given-names>L.</given-names></name><name><surname>Dow</surname><given-names>P.</given-names></name><name><surname>Turgeon</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice</article-title>. <source>Pharmaceutics</source>
<volume>12</volume>, <fpage>846</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12090846</pub-id>
<pub-id pub-id-type="pmid">32899642</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Didziapetris</surname><given-names>R.</given-names></name><name><surname>Dapkunas</surname><given-names>J.</given-names></name><name><surname>Sazonovas</surname><given-names>A.</given-names></name><name><surname>Japertas</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Trainable structure&#x02013;activity relationship model for virtual screening of CYP3A4 inhibition</article-title>. <source>J. computer-aided Mol. Des.</source>
<volume>24</volume>, <fpage>891</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-010-9381-1</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ekins</surname><given-names>S.</given-names></name><name><surname>Bravi</surname><given-names>G.</given-names></name><name><surname>Binkley</surname><given-names>S.</given-names></name><name><surname>Gillespie</surname><given-names>J. S.</given-names></name><name><surname>Ring</surname><given-names>B. J.</given-names></name><name><surname>Wikel</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Three-and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>290</volume>, <fpage>429</fpage>&#x02013;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1016/s0022-3565(24)34917-1</pub-id>
<pub-id pub-id-type="pmid">10381809</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ekroos</surname><given-names>M.</given-names></name><name><surname>Sj&#x000f6;gren</surname><given-names>T.</given-names></name></person-group> (<year>2006</year>). <article-title>Structural basis for ligand promiscuity in cytochrome P450 3A4</article-title>. <source>Proc. Natl. Acad. Sci.</source>
<volume>103</volume>, <fpage>13682</fpage>&#x02013;<lpage>13687</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0603236103</pub-id>
<pub-id pub-id-type="pmid">16954191</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faramarzi</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>M. T.</given-names></name><name><surname>Volpe</surname><given-names>D. A.</given-names></name><name><surname>Cross</surname><given-names>K. P.</given-names></name><name><surname>Chakravarti</surname><given-names>S.</given-names></name><name><surname>Stavitskaya</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Development of QSAR models to predict blood-brain barrier permeability</article-title>. <source>Front. Pharmacol.</source>
<volume>13</volume>, <fpage>1040838</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.1040838</pub-id>
<pub-id pub-id-type="pmid">36339562</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fontana</surname><given-names>E.</given-names></name><name><surname>Dansette</surname><given-names>P. M.</given-names></name><name><surname>Poli</surname><given-names>S. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity</article-title>. <source>Curr. Drug Metab.</source>
<volume>6</volume>, <fpage>413</fpage>&#x02013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.2174/138920005774330639</pub-id>
<pub-id pub-id-type="pmid">16248836</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galetin</surname><given-names>A.</given-names></name><name><surname>Clarke</surname><given-names>S. E.</given-names></name><name><surname>Houston</surname><given-names>J. B.</given-names></name></person-group> (<year>2003</year>). <article-title>Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine</article-title>. <source>Drug Metabolism Dispos.</source>
<volume>31</volume>, <fpage>1108</fpage>&#x02013;<lpage>1116</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.31.9.1108</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Hansch</surname><given-names>C.</given-names></name></person-group> (<year>1996</year>). <article-title>QSAR of P450 oxidation: on the value of comparing k cat and K m with k cat/K m</article-title>. <source>Drug metab. Rev.</source>
<volume>28</volume>, <fpage>513</fpage>&#x02013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.3109/03602539608994017</pub-id>
<pub-id pub-id-type="pmid">8959390</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gay</surname><given-names>S. C.</given-names></name><name><surname>Roberts</surname><given-names>A. G.</given-names></name><name><surname>Halpert</surname><given-names>J. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR</article-title>. <source>Future Med. Chem.</source>
<volume>2</volume>, <fpage>1451</fpage>&#x02013;<lpage>1468</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.10.229</pub-id>
<pub-id pub-id-type="pmid">21103389</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giacomini</surname><given-names>K. M.</given-names></name><name><surname>Krauss</surname><given-names>R. M.</given-names></name><name><surname>Roden</surname><given-names>D. M.</given-names></name><name><surname>Eichelbaum</surname><given-names>M.</given-names></name><name><surname>Hayden</surname><given-names>M. R.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name></person-group> (<year>2007</year>). <article-title>When good drugs go bad</article-title>. <source>Nature</source>
<volume>446</volume>, <fpage>975</fpage>&#x02013;<lpage>977</lpage>. <pub-id pub-id-type="doi">10.1038/446975a</pub-id>
<pub-id pub-id-type="pmid">17460642</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>E.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Shah</surname><given-names>P.</given-names></name><name><surname>Torimoto-Katori</surname><given-names>N.</given-names></name><name><surname>Zakharov</surname><given-names>A.</given-names></name><name><surname>Nguy&#x01ec5;n</surname><given-names>&#x000d0;.-T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Development of robust quantitative structure-activity relationship models for CYP2C9, CYP2D6, and CYP3A4 catalysis and inhibition</article-title>. <source>Drug Metabolism Dispos.</source>
<volume>49</volume>, <fpage>822</fpage>&#x02013;<lpage>832</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.120.000320</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guengerich</surname><given-names>F. P.</given-names></name></person-group> (<year>2001</year>). <article-title>Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity</article-title>. <source>Chem. Res. Toxicol.</source>
<volume>14</volume>, <fpage>611</fpage>&#x02013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1021/tx0002583</pub-id>
<pub-id pub-id-type="pmid">11409933</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guengerich</surname><given-names>F. P.</given-names></name></person-group> (<year>2022</year>). <article-title>Inhibition of cytochrome P450 enzymes by drugs&#x02014;molecular basis and practical applications</article-title>. <source>Biomol. and Ther.</source>
<volume>30</volume>, <fpage>1</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.4062/biomolther.2021.102</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hansch</surname><given-names>C.</given-names></name><name><surname>Mekapati</surname><given-names>S. B.</given-names></name><name><surname>Kurup</surname><given-names>A.</given-names></name><name><surname>Verma</surname><given-names>R. P.</given-names></name></person-group> (<year>2004</year>). <article-title>QSAR of cytochrome P450</article-title>. <source>Drug metab. Rev.</source>
<volume>36</volume>, <fpage>105</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1081/dmr-120028428</pub-id>
<pub-id pub-id-type="pmid">15072440</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hansch</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group> (<year>1993</year>). <article-title>Quantitative structure-activity relationships of cytochrome P-450</article-title>. <source>Drug metab. Rev.</source>
<volume>25</volume>, <fpage>1</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.3109/03602539308993972</pub-id>
<pub-id pub-id-type="pmid">8449144</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hansten</surname><given-names>P. D.</given-names></name><name><surname>Horn</surname><given-names>J. R.</given-names></name><name><surname>Korth-Bradley</surname><given-names>J. M.</given-names></name></person-group> (<year>2010</year>). <article-title>The top 100 drug interactions: a guide to patient management, 2010 edition</article-title>. <source>Ann. Pharmacother.</source>
<volume>44</volume>, <fpage>1119</fpage>&#x02013;<lpage>1120</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1p108</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hillebrecht</surname><given-names>A.</given-names></name><name><surname>Muster</surname><given-names>W.</given-names></name><name><surname>Brigo</surname><given-names>A.</given-names></name><name><surname>Kansy</surname><given-names>M.</given-names></name><name><surname>Weiser</surname><given-names>T.</given-names></name><name><surname>Singer</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Comparative evaluation of <italic>in silico</italic> systems for ames test mutagenicity prediction: scope and limitations</article-title>. <source>Chem. Res. Toxicol.</source>
<volume>24</volume>, <fpage>843</fpage>&#x02013;<lpage>854</lpage>. <pub-id pub-id-type="doi">10.1021/tx2000398</pub-id>
<pub-id pub-id-type="pmid">21534561</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoemann</surname><given-names>M.</given-names></name><name><surname>Wilson</surname><given-names>N.</given-names></name><name><surname>Argiriadi</surname><given-names>M.</given-names></name><name><surname>Banach</surname><given-names>D.</given-names></name><name><surname>Burchat</surname><given-names>A.</given-names></name><name><surname>Calderwood</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Synthesis and optimization of furano [3, 2-d] pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors</article-title>. <source>Bioorg. and Med. Chem. Lett.</source>
<volume>26</volume>, <fpage>5562</fpage>&#x02013;<lpage>5567</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2016.09.077</pub-id>
<pub-id pub-id-type="pmid">27789138</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>J. P.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Trager</surname><given-names>W. F.</given-names></name><name><surname>Rettie</surname><given-names>A. E.</given-names></name></person-group> (<year>1996</year>). <article-title>Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9</article-title>. <source>Drug Metabolism Dispos.</source>
<volume>24</volume>, <fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.2133/dmpk.DMPK-12-RG-133</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A.</given-names></name><name><surname>Dalvie</surname><given-names>D.</given-names></name><name><surname>Obach</surname><given-names>R.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Pathways of reactive metabolite formation with toxicophores/&#x02010;structural alerts</article-title>. <source>React. Drug Metab.</source>, <fpage>93</fpage>&#x02013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1002/9783527655748.ch5</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name></person-group> (<year>2008</year>). &#x0201c;<article-title>Role of bioactivation in idiosyncratic drug toxicity: structure&#x02013;toxicity relationships</article-title>,&#x0201d; in <source>Advances in bioactivation research</source>. Editor <person-group person-group-type="editor"><name><surname>Elfarra</surname><given-names>A.</given-names></name></person-group> (<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>1</fpage>&#x02013;<lpage>29</lpage>.</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Designing around structural alerts in drug discovery</article-title>. <source>J. Med. Chem.</source>
<volume>63</volume>, <fpage>6276</fpage>&#x02013;<lpage>6302</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00917</pub-id>
<pub-id pub-id-type="pmid">31497963</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><name><surname>Dalvie</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Predicting toxicities of reactive metabolite-positive drug candidates</article-title>. <source>Annu. Rev. Pharmacol. Toxicol.</source>
<volume>55</volume>, <fpage>35</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010814-124720</pub-id>
<pub-id pub-id-type="pmid">25292426</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><name><surname>Driscoll</surname><given-names>J. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Is there enough evidence to classify cycloalkyl amine substituents as structural alerts?</article-title>
<source>Biochem. Pharmacol.</source>
<volume>174</volume>, <fpage>113796</fpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2020.113796</pub-id>
<pub-id pub-id-type="pmid">31926938</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><name><surname>Gardner</surname><given-names>I.</given-names></name><name><surname>Obach</surname><given-names>R. S.</given-names></name><name><surname>Shaffer</surname><given-names>C. L.</given-names></name><name><surname>Callegari</surname><given-names>E.</given-names></name><name><surname>Henne</surname><given-names>K. R.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>A comprehensive listing of bioactivation pathways of organic functional groups</article-title>. <source>Curr. Drug Metab.</source>
<volume>6</volume>, <fpage>161</fpage>&#x02013;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.2174/1389200054021799</pub-id>
<pub-id pub-id-type="pmid">15975040</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><name><surname>Obach</surname><given-names>R. S.</given-names></name><name><surname>Maurer</surname><given-names>T. S.</given-names></name></person-group> (<year>2007</year>). <article-title>Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions</article-title>. <source>Curr. Drug Metab.</source>
<volume>8</volume>, <fpage>407</fpage>&#x02013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.2174/138920007780866807</pub-id>
<pub-id pub-id-type="pmid">17584015</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><name><surname>Soglia</surname><given-names>J. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Minimising the potential for metabolic activation in drug discovery</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source>
<volume>1</volume>, <fpage>91</fpage>&#x02013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1517/17425255.1.1.91</pub-id>
<pub-id pub-id-type="pmid">16922655</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P.</given-names></name><name><surname>Chamberlin</surname><given-names>A. R.</given-names></name><name><surname>Poulos</surname><given-names>T. L.</given-names></name><name><surname>Sevrioukova</surname><given-names>I. F.</given-names></name></person-group> (<year>2016</year>). <article-title>Structure-based inhibitor design for evaluation of a CYP3A4 pharmacophore model</article-title>. <source>J. Med. Chem.</source>
<volume>59</volume>, <fpage>4210</fpage>&#x02013;<lpage>4220</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01146</pub-id>
<pub-id pub-id-type="pmid">26371436</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Landry</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>M. T.</given-names></name><name><surname>Kruhlak</surname><given-names>N. L.</given-names></name><name><surname>Cross</surname><given-names>K. P.</given-names></name><name><surname>Saiakhov</surname><given-names>R.</given-names></name><name><surname>Chakravarti</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<volume>109</volume>, <fpage>104488</fpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2019.104488</pub-id>
<pub-id pub-id-type="pmid">31586682</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D. F.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Human CYPs involved in drug metabolism: structures, substrates and binding affinities</article-title>. <source>Expert Opin. drug metabolism and Toxicol.</source>
<volume>6</volume>, <fpage>661</fpage>&#x02013;<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1517/17425251003674380</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D. F.</given-names></name><name><surname>Modi</surname><given-names>S.</given-names></name><name><surname>Dickins</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism</article-title>. <source>Drug metabolism drug Interact.</source>
<volume>18</volume>, <fpage>221</fpage>&#x02013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1515/dmdi.2001.18.3-4.221</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>P.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Rodrigues</surname><given-names>A. D.</given-names></name><name><surname>Rushmore</surname><given-names>T. H.</given-names></name><name><surname>Baillie</surname><given-names>T. A.</given-names></name><name><surname>Shou</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4</article-title>. <source>Drug metabolism Dispos.</source>
<volume>29</volume>, <fpage>1473</fpage>&#x02013;<lpage>1479</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.29.11.1473</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O Nettleton</surname><given-names>D.</given-names></name><name><surname>J Einolf</surname><given-names>H.</given-names></name></person-group> (<year>2011</year>). <article-title>Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development</article-title>. <source>Curr. Top. Med. Chem.</source>
<volume>11</volume>, <fpage>382</fpage>&#x02013;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.2174/156802611794480882</pub-id>
<pub-id pub-id-type="pmid">21320066</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orr</surname><given-names>S. T.</given-names></name><name><surname>Ripp</surname><given-names>S. L.</given-names></name><name><surname>Ballard</surname><given-names>T. E.</given-names></name><name><surname>Henderson</surname><given-names>J. L.</given-names></name><name><surname>Scott</surname><given-names>D. O.</given-names></name><name><surname>Obach</surname><given-names>R. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure&#x02013;activity relationships and discovery strategies to mitigate drug&#x02013;drug interaction risks</article-title>. <source>J. Med. Chem.</source>
<volume>55</volume>, <fpage>4896</fpage>&#x02013;<lpage>4933</lpage>. <pub-id pub-id-type="doi">10.1021/jm300065h</pub-id>
<pub-id pub-id-type="pmid">22409598</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Aoyama</surname><given-names>R.</given-names></name><name><surname>Schrag</surname><given-names>M.</given-names></name><name><surname>Trager</surname><given-names>W. F.</given-names></name><name><surname>Rettie</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>J. P.</given-names></name></person-group> (<year>2000</year>). <article-title>A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions</article-title>. <source>J. Med. Chem.</source>
<volume>43</volume>, <fpage>2789</fpage>&#x02013;<lpage>2796</lpage>. <pub-id pub-id-type="doi">10.1021/jm000048n</pub-id>
<pub-id pub-id-type="pmid">10956186</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riley</surname><given-names>R. J.</given-names></name><name><surname>Grime</surname><given-names>K.</given-names></name><name><surname>Weaver</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Time-dependent CYP inhibition</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source>
<volume>3</volume>, <fpage>51</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1517/17425255.3.1.51</pub-id>
<pub-id pub-id-type="pmid">17269894</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>G.</given-names></name><name><surname>Myatt</surname><given-names>G. J.</given-names></name><name><surname>Johnson</surname><given-names>W. P.</given-names></name><name><surname>Cross</surname><given-names>K. P.</given-names></name><name><surname>Blower</surname><given-names>P. E.</given-names></name></person-group> (<year>2000</year>). <article-title>LeadScope: software for exploring large sets of screening data</article-title>. <source>J. Chem. Inf. Comput. Sci.</source>
<volume>40</volume>, <fpage>1302</fpage>&#x02013;<lpage>1314</lpage>. <pub-id pub-id-type="doi">10.1021/ci0000631</pub-id>
<pub-id pub-id-type="pmid">11128088</pub-id>
</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roy</surname><given-names>K.</given-names></name><name><surname>Roy</surname><given-names>P. P.</given-names></name></person-group> (<year>2009</year>). <article-title>Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>44</volume>, <fpage>2913</fpage>&#x02013;<lpage>2922</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2008.12.004</pub-id>
<pub-id pub-id-type="pmid">19128860</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudik</surname><given-names>A.</given-names></name><name><surname>Dmitriev</surname><given-names>A.</given-names></name><name><surname>Lagunin</surname><given-names>A.</given-names></name><name><surname>Filimonov</surname><given-names>D.</given-names></name><name><surname>Poroikov</surname><given-names>V.</given-names></name></person-group> (<year>2022</year>). <article-title>Computational prediction of inhibitors and inducers of the major isoforms of cytochrome P450</article-title>. <source>Molecules</source>
<volume>27</volume>, <fpage>5875</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27185875</pub-id>
<pub-id pub-id-type="pmid">36144612</pub-id>
</mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sridhar</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Foroozesh</surname><given-names>M.</given-names></name><name><surname>Klein Stevens</surname><given-names>C. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies</article-title>. <source>Molecules</source>
<volume>17</volume>, <fpage>9283</fpage>&#x02013;<lpage>9305</lpage>. <pub-id pub-id-type="doi">10.3390/molecules17089283</pub-id>
<pub-id pub-id-type="pmid">22864238</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stepan</surname><given-names>A. F.</given-names></name><name><surname>Walker</surname><given-names>D. P.</given-names></name><name><surname>Bauman</surname><given-names>J.</given-names></name><name><surname>Price</surname><given-names>D. A.</given-names></name><name><surname>Baillie</surname><given-names>T. A.</given-names></name><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</article-title>. <source>Chem. Res. Toxicol.</source>
<volume>24</volume>, <fpage>1345</fpage>&#x02013;<lpage>1410</lpage>. <pub-id pub-id-type="doi">10.1021/tx200168d</pub-id>
<pub-id pub-id-type="pmid">21702456</pub-id>
</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sudsakorn</surname><given-names>S.</given-names></name><name><surname>Bahadduri</surname><given-names>P.</given-names></name><name><surname>Fretland</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>2020 FDA drug-drug interaction guidance: a comparison analysis and action plan by pharmaceutical industrial scientists</article-title>. <source>Curr. drug Metab.</source>
<volume>21</volume>, <fpage>403</fpage>&#x02013;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.2174/1389200221666200620210522</pub-id>
<pub-id pub-id-type="pmid">32562522</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sutter</surname><given-names>A.</given-names></name><name><surname>Amberg</surname><given-names>A.</given-names></name><name><surname>Boyer</surname><given-names>S.</given-names></name><name><surname>Brigo</surname><given-names>A.</given-names></name><name><surname>Contrera</surname><given-names>J. F.</given-names></name><name><surname>Custer</surname><given-names>L. L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Use of <italic>in silico</italic> systems and expert knowledge for structure-based assessment of potentially mutagenic impurities</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<volume>67</volume>, <fpage>39</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2013.05.001</pub-id>
<pub-id pub-id-type="pmid">23669331</pub-id>
</mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Testa</surname><given-names>B.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name></person-group> (<year>1981</year>). <article-title>Inhibitors of cytochrome P-450s and their mechanism of action</article-title>. <source>Drug metab. Rev.</source>
<volume>12</volume>, <fpage>1</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.3109/03602538109011082</pub-id>
<pub-id pub-id-type="pmid">7028434</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vandenbrink</surname><given-names>B. M.</given-names></name><name><surname>Foti</surname><given-names>R. S.</given-names></name><name><surname>Rock</surname><given-names>D. A.</given-names></name><name><surname>Wienkers</surname><given-names>L. C.</given-names></name><name><surname>Wahlstrom</surname><given-names>J. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Prediction of CYP2D6 drug interactions from <italic>in vitro</italic> data: evidence for substrate-dependent inhibition</article-title>. <source>Drug Metabolism Dispos.</source>
<volume>40</volume>, <fpage>47</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.111.041210</pub-id>
</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veith</surname><given-names>H.</given-names></name><name><surname>Southall</surname><given-names>N.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>James</surname><given-names>T.</given-names></name><name><surname>Fayne</surname><given-names>D.</given-names></name><name><surname>Artemenko</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries</article-title>. <source>Nat. Biotechnol.</source>
<volume>27</volume>, <fpage>1050</fpage>&#x02013;<lpage>1055</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1581</pub-id>
<pub-id pub-id-type="pmid">19855396</pub-id>
</mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>L. P.</given-names></name><name><surname>Zhang</surname><given-names>X. Z.</given-names></name><name><surname>Huang</surname><given-names>S. Q.</given-names></name><name><surname>Bartlam</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>S. F.</given-names></name></person-group> (<year>2009</year>). <article-title>New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme</article-title>. <source>Drug Metab. Rev.</source>
<volume>41</volume>, <fpage>573</fpage>&#x02013;<lpage>643</lpage>. <pub-id pub-id-type="doi">10.1080/03602530903118729</pub-id>
<pub-id pub-id-type="pmid">19645588</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>R. W.</given-names></name><name><surname>Newton</surname><given-names>D. J.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Atkins</surname><given-names>W. M.</given-names></name><name><surname>Lu</surname><given-names>A. Y.</given-names></name></person-group> (<year>2000</year>). <article-title>Human cytochrome P-450 3A4: <italic>in vitro</italic> drug-drug interaction patterns are substrate-dependent</article-title>. <source>Drug Metabolism Dispos.</source>
<volume>28</volume>, <fpage>360</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1016/s0090-9556(24)15374-3</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wienkers</surname><given-names>L. C.</given-names></name><name><surname>Heath</surname><given-names>T. G.</given-names></name></person-group> (<year>2005</year>). <article-title>Predicting <italic>in vivo</italic> drug interactions from <italic>in vitro</italic> drug discovery data</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>4</volume>, <fpage>825</fpage>&#x02013;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1851</pub-id>
<pub-id pub-id-type="pmid">16224454</pub-id>
</mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Gui</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Development of <italic>in silico</italic> models for predicting potential time-dependent inhibitors of cytochrome P450 3A4</article-title>. <source>Mol. Pharm.</source>
<volume>20</volume>, <fpage>194</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00571</pub-id>
<pub-id pub-id-type="pmid">36458739</pub-id>
</mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>A. M.</given-names></name><name><surname>Idle</surname><given-names>J. R.</given-names></name><name><surname>Gonzalez</surname><given-names>F. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates</article-title>. <source>Drug Metab. Rev.</source>
<volume>36</volume>, <fpage>243</fpage>&#x02013;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1081/dmr-120034000</pub-id>
<pub-id pub-id-type="pmid">15237854</pub-id>
</mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Balani</surname><given-names>S. K.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Cui</surname><given-names>D.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Humphreys</surname><given-names>W. G.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group</article-title>. <source>Drug Metab. Dispos.</source>
<volume>43</volume>, <fpage>620</fpage>&#x02013;<lpage>630</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.114.059345</pub-id>
<pub-id pub-id-type="pmid">25655830</pub-id>
</mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Rao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Qiu</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation</article-title>. <source>Drug Metab. Rev.</source>
<volume>52</volume>, <fpage>501</fpage>&#x02013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1080/03602532.2020.1828910</pub-id>
<pub-id pub-id-type="pmid">33043714</pub-id>
</mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name></person-group> (<year>2018</year>). <article-title>Drug metabolism in drug discovery and development</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>8</volume>, <fpage>721</fpage>&#x02013;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2018.04.003</pub-id>
<pub-id pub-id-type="pmid">30245961</pub-id>
</mixed-citation></ref></ref-list></back></article>